Volume 24, Number 7—July 2018
Research
Pediatric Complicated Pneumonia Caused by Streptococcus pneumoniae Serotype 3 in 13-Valent Pneumococcal Conjugate Vaccinees, Portugal, 2010–2015
Table 1
Vaccine |
Start of vaccination scheme |
Primary immunization course |
Booster vaccination |
---|---|---|---|
PCV7 |
2–6 mo | 3 doses, at 2, 4, and 6 mo | 12–15 mo |
7–11 mo | 2 doses | Booster dose at 12 mo† | |
12–23 mo | 2 doses‡ | NA | |
24–59 mo |
Risk group only: 2 doses |
NA |
|
PCV13 | 2–6 mo | 2 or 3 doses§ | 11–15 mo¶ |
7–11 mo | 2 doses§ | 11–15 mo¶ | |
12–23 mo | 2 doses‡ | NA | |
>24 mo | 1 dose | NA |
*NA, not applicable; PCV, pneumococcal conjugate vaccine; PCV7, 7-valent PCV; PCV13, 13-valent PCV.
†8 weeks after the second dose.
‡>8 weeks apart.
§Minimum interval between doses 4 weeks.
¶Minimum interval from last dose 8 weeks.
1Current affiliation: Centro de Investigação Interdisciplinar em Sanidade Animal (CIISA), Faculdade de Medicina Veterinária, Universidade de Lisboa, Lisboa, Portugal.
2Members of the group are listed at the end of this article.
Page created: June 18, 2018
Page updated: June 18, 2018
Page reviewed: June 18, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.